Introduction
Vascular smooth muscle cells (VSMCs) play a key role in the processes of multiple vascular pathologies. Different from terminally differentiated cells, VSMCs possess a distinctive property of plasticity that allows the phenotypic shift from a differentiated/contractile state towards a dedifferentiated/synthetic state. 1 Although the plasticity or differentiation of VSMCs is necessarily required for vascular development and repair, aberrant phenotypic transition has been established to contribute to a great variety of vascular disorders, such as atherosclerosis and aneurysm. 2, 3 Despite the importance of VSMC differentiation in the modulation of vascular function in health and disease conditions, the underlying molecular mechanisms remain incompletely understood. Macrophage migration inhibitory factor (MIF) is a potent proinflammatory cytokine that is mainly expressed and released by immune cells, but also from other cell types, including VSMCs and endothelial cells. 4 MIF is critical for the regulation of immunologic and inflammatory diseases. Importantly, recent clinical studies have identified a central role for MIF in the pathogenesis of vascular diseases. [5] [6] [7] Abbrent expression and gene polymorphisms of MIF have been associated with coronary arterial diseases. 8, 9 Schober et al. 10 reported that MIF inhibition using a neutralizing antibody led to reduced vascular neointimal formation in atherosclerosis-susceptible mice. Furthermore, genetic deletion of MIF exerts beneficial effects on reversing the progression of pulmonary vascular remodelling, thus, suggesting a deteriorate role of MIF in the vessels of both systemic and pulmonary circuits. 11 Although human studies and functional animal experiments have implied the involvement of MIF in angiopathies, the majority of these reports focused on its inflammatory features, such as recruitment and adhesion of monocyte, while little information is currently available regarding the direct effects of MIF on differentiation and biological function of VSMCs, which are fundamental for the progression of multiple arterial diseases. Moreover, despite the close relationships between MIF and a wide range of arterial abnormalities, a universal interpretation of its extensive and detrimental effects in the world of vascular disease is absence.
VSMCs are known to modify their phenotype when challenged with several inflammatory mediators. 12, 13 As one of the first proinflammatory cytokines to be identified, we hypothesized that MIF contributes to VSMC transition, therefore plays a pernicious role in various arterial diseases. Our results demonstrate that MIF triggers VSMC dedifferentiation by impairing a novel p68-serum response factor (SRF) axis, stimulates VSMC migration, and promotes vascular remodelling. Anti-MIF treatment using ISO-1 reverses VSMC transition, preserves vascular function, and inhibits remodelling, which highlights its potential therapeutic benefit in phenotype-related arterial diseases.
Methods
The detailed methods are available as an Online Data Supplement.
Materials
Recombinant MIF was purchased from R&D. 4,5-Dihydro-3-(4-hydroxyphenyl)-5-isoxazoleacetic acid methyl ester (ISO-1) was obtained from Santa Cruz Biotechnology. Monoclonal antibodies targeting calponin (CNN1) and smooth muscle a-actin (SMA) were bought from Sigma-Aldrich. Antibodies against smooth muscle 22a (SM22a) and smooth muscle myosin heavy chain (MYH11) were from Abcam (UK). An expanded list of materials used can be found in the Online Data Supplement.
Animal experiments
All animal experimental procedures conformed to the guidelines of the Third Military Medical University Animal Care and Use Committee. The artery injury model was established in male Sprague-Dawley rats; briefly, the left common carotid arteries of anesthetized rats were carefully dissected and completely injured by using an arterial embolectomy balloon catheter.
Once the rat carotid arteries were finely separated, the ice-cold F-127 pluronic gel (Sigma) mixed with cytokines were applied to the adventitial surface of rat carotid arteries for 24 h. The arteries were harvested at indicated time-points for the predesigned assays.
Isolation and culture of rat VSMCs
Rat VSMCs were isolated from cultured vessel explants of Sprague-Dawley rats. VSMCs were cultured in Dulbecco's modified essential media (DMEM) (Hyclone) supplemented with 10% foetal bovine serum (FBS, Gibco). Cells from passages 3 through 10 were used in these experiments.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from tissues or cultured VSMCs with TRIZOL reagents (Takara, Japan). Real-time PCR was performed using SYBR green reagent (Takara) and ABI 7500 system (Applied Biosystems). Primers of target genes were synthesized by Shangon Biotech (Shanghai, China). Gene expressions were normalized to b-actin.
Western blot
Cellular or tissue extracts were resolved by 10% SDS-PAGE, then blotted onto polyvinylidene difluoridemembrane (Millpore, the Netherlands) and probed with specific antibodies. Signals were detected through enhanced chemiluminescence.
Coimmunoprecipitation
The protein samples from rat aorta and cultured VSMCs were lysed by the specific lysis buffer and immunoprecipitated using the indicated antibodies. Then, the precipitated proteins were extracted following the manufacturer's instructions and detected by SDS-PAGE.
EMSA
EMSA was performed using the Light-shift Chemiluminescent EMSA Kit (Pierce Chemical, Rockford, IL). A synthetic double-stranded wild-type oligonucleotide from rat SM22 upstream sequences and a mutant oligonucleotide of corresponding length in which the SRF binding site was mutated, were labelled with biotin and incubated with the prepared nuclear proteins.
Statistical analysis
All data are expressed as mean ± SEM from 3 or more independent experiments and analysed with PASW Statistic 21 (SPSS Inc). Data between two groups were compared using two-tailed Student's t-test. Multiple comparisons utilized one-way ANOVA followed by Student-Newman-Keuls test. P < 0.05 was considered as significant difference.
Results

Association of MIF and VSMC differentiation in vivo and in vitro
To determine whether MIF was involved in dedifferentiation process of VSMCs, we investigated the expression level of MIF in the rat models of vascular remodelling. As shown in Figure 1A , MIF expression was dramatically increased in the injured arteries at 14 days post-injury, correlated with markedly suppressed protein expression of VSMC differentiation markers, such as CNN1, SM22a, MYH11, and SMA, as compared to sham-operated vessels. No significant differences in MIF expression were detected between control and the injured vessels after 28 days, accompanied by the restored expression of VSMC differentiation markers, which suggested a negative link between MIF expression and VSMC-specific markers in vivo. Similarly, we found that high fat diet greatly increased MIF expression and suppressed VSMC-specific proteins in aorta from Apolipoprotein E-deficient mice (Supplementary ma terial online, Figure S1A ).
To further verify the above observations in vitro, cultured rat VSMCs were exposed to either platelet-derived growth factor-BB or hypoxia for 24 h, which is the most widely accepted approach for studies of VSMC differentiation. The western blots showed that MIF expression were increased by 25 ng/mL PDGF-BB and 1% hypoxic stimulation, while the differentiation markers were greatly reduced, as compared to untreated VSMCs ( Figure 1B, Supplementary material online, Figure S1B 
Serum starvation, known to prompt VSMC differentiation, significantly downregulated MIF expression with concomitantly increased VSMC contractile proteins (Supplementary material online, Figure S1C ). In addition, we observed a marked increase of immunoreactive MIF content in the culture supernatants of VSMCs stimulated by PDGF-BB that peaked at 6 h after treatment (Supplementary material online, Figure S1D) . Therefore, our data suggest that MIF is negatively associated with the expression of the differentiation markers during VSMC phenotypic switching.
MIF induces dedifferentiation of VSMC in vitro
To test whether MIF could directly trigger VSMC dedifferentiation, quiescent VSMCs were incubated with different concentrations of recombinant MIF for 24 h. Quantitative real-time RT-PCR, western blot and immunofluorescence analyses in cultured VSMCs showed that extracellular application of MIF induced dose-dependent suppression of VSMCspecific markers: CNN1, SM22a, MYH11, SMA, Caldesmon, and Smoothelin ( Figure 1C and D, Supplementary material online, Figure S2A -C). In addition, MIF treatment also strongly suppressed the expression of VSMC contractile proteins in a time-dependent manner, becoming significant at 3 h after stimulation (Supplementary material online, Figure S2D ). Finally, we found that MIF augmented migration of VSMCs and induced the activation of matrix metalloproteinase-2 (MMP-2), but had no effects on cell proliferation (Supplementary material online, Figure S3A -E).
14 Next, we examined the effects of ISO-1, a small molecule MIF antagonist, 15 on PDGF-BB-and hypoxia-induced VSMC differentiation.
As expected, inhibition of MIF activity using ISO-1 rescued the repression of VSMC-specific markers in response to PDGF-BB and hypoxia ( Figure 1E , Supplementary material online, Figure S4A ). Similarly, downregulation of MIF using siRNA increased VSMC marker protein expressions (Supplementary material online, Figure S4B ). Thus, these results further support MIF as being a negative regulator of VSMC differentiation. CD74 is the major receptor for MIF. 16 Previous study has reported its expression in vascular cells including VSMC, and it has been shown to prompt the inflammatory cascade during atherogenesis. 17 Here, we demonstrated that CD74 was upregulated in PDGF-BB-induced dedifferentiated VSMC (Supplementary material online, Figure S5A ). After successfully downregulating CD74 expression in VSMC using siRNA, we treated these cells with 25 ng/mL MIF (Supplementary material online, Figure S5B and C). The result indicated that CD74 downregulation can reverse MIF-triggered phenotypic modulation, which suggests that CD74 could mediate VSMC transition induced by MIF.
MIF promotes VSMC dedifferentiation in vivo
Motivated by the heightened dedifferentiation of VSMCs with MIF stimulation in vitro, we next asked whether MIF could also suppress VSMC 
differentiation markers in vivo. By adopting a pluronic F-127 gel system, recombinant MIF or vehicle were applied to the adventitia of rat carotid arteries, as previously reported. 18 After 24 h of treatment, MIF caused significant repression of CNN1, SM22a, MYH11, SMA, Caldesmon, and Smoothelin in a concentration-dependent manner compared to the vehicle-treated vessels, as determined by quantitative real-time RT-PCR and western blot ( Figure 2A and B, Supplementary material online, Figure S6A ), but 24 h application of MIF did not lead to vascular remodelling (data not shown). In addition, the intensity of immunohistochemical staining for the differentiation markers was significantly lower in MIF-treated carotid arteries than in those receiving vehicle ( Figure 2C ). Furthermore, vehicle or MIF-treated carotid arteries were dissected from rats and cut into rings and vascular contractility was measured using a Power Lab isolated organ system. We found that MIF significantly suppressed vascular contraction in response to norepinephrine ( Figure 2D and E), but it had no significant impacts on vascular relaxation (Supplementary material online, Figure S6B and C).
Anit-MIF treatment reverses VSMC dedifferentiation and vascular remodelling
Next, we evaluated the effects of MIF blockade on VSMC differentiation in vivo by treating rat carotid injury models with either ISO-1 or MIF siRNA. The reduction of VSMC contractile proteins in rat carotid arteries due to balloon injury was largely reversed by both ISO-1 and MIF siRNA administration ( Figure 3A , Supplementary material online, Figure S6D ). Anti-MIF treatment also attenuated the decrease of contractility following vascular injury ( Figure 3B and C) . Furthermore, we found that anti-MIF treatment also reduced vascular remodelling ( Figure  3D , Supplementary material online, Figure S6E and F). Collectively, our results clearly demonstrate that MIF significantly reduces VSMC differentiation markers expression in vivo.
p68 protein expression in VSMCs is repressed by MIF
After observing the marked suppressive effects of MIF on VSMC differentiation proteins, we attempted to explore the potential mechanisms involved. p68 is an adenosine triphosphate-dependent RNA helicase, which participates in all the biochemical steps that involve RNA. 19 Other than modulating RNA structure, p68 has been shown to play a crucial role in the regulation of cell growth and organ differentiation. Therefore, we wondered whether p68 was also involved in the process of MIFinduced VSMC dedifferentiation. Intriguingly, our results showed that MIF dose-dependently downregulated both mRNA and protein expression of p68, whereas MIF siRNA transfection upregulated p68 protein in VSMCs ( Figure 4A and B, Supplementary material online, Figure S7A ). Additionally, recombinant MIF induced a time-dependent suppression of p68 in primary cultured VSMCs ( Figure 4C) . Consistent with this, in vivo application of MIF to rat carotid artery significantly decreased p68 expression after 24 h of treatment ( Figure 4D ).
MIF regulates p68 by activating p38 and JNK MAPKs
It has been demonstrated that MIF promoted the sustained activation of MAPK pathway, which regulated the expression of a wide range of genes. 20 Here, we showed that MIF activated Rac1 and the downstream MAPK pathway in rat VSMCs, but had little impacts on RhoA (Supplementary material online, Figure S7B -E). To investigate the possibility that p68 expression is also modulated by MIF-elicited MAPK signalling in VSMCs, we applied SP600125, SB203580 or U0126 to MIFtreated VSMCs, in order to block c-Jun N-terminal kinase (JNK), p38 and extracellular signal-regulated kinase (ERK) MAPKs, respectively. We found that SB203580 and SP600125, but not U0126, reversed the suppression of p68 mRNA and protein expressions evoked by MIF ( Figure  5A-C) , accompanied by upregulation of VSMC marker proteins expression ( Figure 5D and E). However, these inhibitors alone did not affect either p68 expression or VSMC differentiation (Supplementary material online, Figure S8A -D). The findings illustrate that MIF causes profound repression of p68 in VSMCs through activation of p38 and JNK MAPKs.
Based on the results, we speculated upon the possibility of p68 protein as a down-stream mediator of MIF-induced VSMC transition.
p68 is essential for maintenance of VSMC differentiated phenotype
To validate the effect of p68 in MIF-induced VSMC transition, we first knockdown p68 by specific small interfering (si)RNA; it resulted transfection of p68-specific siRNA abrogated p68 expression efficiently (Supplementary material online, Figure S9A and B). As depicted in Figure  6A , the mRNA levels of VSMC differentiation markers were decreased in parallel. Moreover, p68-specific siRNA but not scrambled siRNA markedly downregulated the protein expression of CNN1, SM22a, MYH11, SMA, Caldesmon, and Smoothelin, as evaluated biochemically and immunofluorescently ( Figure 6B and C, Supplementary material on line, Figure S9C) . The results indicate that VSMCs lacking p68 promote dedifferentiation. To further investigate whether MIF related regulation of VSMC contractile proteins was mediated by p68, cultured VSMCs transfected with scrambled siRNA or p68 siRNA were challenged with Figure 6D ). These in vitro data suggest that MIF inhibition renders VSMC transition mainly through p68. Next, we determined whether overexpression of p68 could reverse VSMC dedifferentiation. Lentiviruses containing GFP or p68-GFP constructs were applied, and overexpression of p68 protein was verified by western blot (Supplementary material online, Figure S10A ). Our results demonstrated that enforced expression of p68 promoted differentiation of VSMCs with markedly upregulated protein expression of VSMC markers CNN1, SM22a, MYH11, SMA, Caldesmon, and Smoothelin (Supplementary material online, Figure S10B and C). To study whether MIF decreased VSMC marker genes expression through p68 suppression, we treated GFP control and p68 overexpressed VSMCs with 25 ng/mL recombinant MIF for 24 h. The western blot analyses revealed that when exposed to MIF, overexpression of p68 retained a differentiated phenotype of VSMCs, with significantly upregulated contractile markers compared to GFP-control ( Figure 6E , Supplementary material online, Figure S10D ). The observation was further strengthened by immunofluorescence, which demonstrated that p68 overexpression circumvented MIF-induced repression of SMA in VSMCs ( Figure 6F) . Altogether, the data strongly support MIF facilitating a differentiated VSMC phenotype via modulation of the p68 expression.
MIF suppresses serum response factor (SRF) in a p68 dependent manner
To further explore the underlying mechanism by which MIF induced VSMC dedifferentiation, we examined its effects on the expression of SRF, which is the master regulator of VSMC-specific genes and of critical importance for maintaining the homeostasis of VSMCs. Of note, realtime RT-PCR and western blot analysis demonstrated that MIF caused concentration-dependent downregulation of both SRF mRNA and 
protein levels in VSMCs, without affecting the expression of the SRF coactivator, myocardin ( Figure 7A and B, Supplementary material online, Figure S11A and B). In addition, the effect of MIF on SRF expression was diminished by SB203580 and SP600125, suggesting a role for JNK and p38 MAPK signalling in MIF-induced suppression of SRF ( Figure 7C and  D) . Knockdown of p68 by RNA interference was associated with prominently decreased SRF, as compared with scrambled control ( Figure 7E , Supplementary material online, Figure S11C ). In contrast, enforced p68 expression reversed MIF-induced suppression of SRF, implicating a p68-dependent mechanism (Supplementary material online, Figure 7F , Supplementary material online, Figure S11D ). MIF (15 or 25 ng/mL) did not significantly affect either the total protein level or phosphorylation of myosin light chain (MLC) in VSMCs, which is potential targets of SRF and has been proved to prompt vascular contraction (Supplementary mater ial online, Figure S11E and F).
p68 interacts with SRF and regulates its binding to VSMC-specific promoter
As demonstrated by confocal laser scanning microscope, MIF directly induced nucleo-cytoplasmic translocation of SRF, a known attribute of VSMC dedifferentiation, 15 which was largely blocked by p68 lentivirus transfection ( Figure 8A) . Interestingly, our immunofluorescence study showed the colocalization of p68 and SRF ( Figure 8B) . To further investigate the potential molecular interaction between p68 and SRF, coimmunoprecipitation assay was performed using the detergent extracts prepared from normal VSMCs and rat aortas. As shown in Figure 8C , western blot analysis of immunoprecipitates demonstrated a specific p68 band brought down by anti-SRF antibody but not by control IgG. In agreement with this observation, treatment with anti-p68 antibody revealed that p68 also precipitated SRF. Thus, p68 was capable of binding to SRF. Next, we attempted to determine whether MIF and p68 would affect the binding of SRF to VSMC-specific promoter regions. Using Electrophoretic Mobility Shift Assay (EMSA), we showed that MIF decreased the recruitment of SRF to the SM22 promoter, whereas p68 overexpression reversed this effect of MIF by increasing the association of SRF with its binding site. Our results indicated that MIF reduced the ability of SRF to bind to the CArG box within VSMC marker promoter by suppressing p68 ( Figure 8D) . Taken together, our data presents evidence that MIF-induced suppression of VSMC differentiation is attributable to inhibition of p68-dependent SRF expression.
Discussion
Although prior reports have proposed a role of MIF in atherosclerosis and VSMC migration, its effect on VSMC phenotypic plasticity remains unclear. [21] [22] [23] [24] To our knowledge, this is the first study showing the involvement of MIF in VSMC dedifferentiation that is the basis for the progression of many vascular diseases, and is closely associated with VSMC biological behaviours, such as contraction, apoptosis, extracellular matrix synthesis and secretion, and proliferation, not only cell migration.
Our study also identifies a previously unreported MAPK-p68-SRF pathway through which MIF regulates VSMC plasticity. Blocking MIF activity by small molecular inhibitor can reverse vascular remodelling by restoring VSMC-specific protein expression, which suggests that biochemically targeting of MIF may be clinically beneficial in phenotype-related vascular diseases. Overall, the results demonstrate a previously undiscovered role of MIF in VSMC homeostasis and pathophysiology.
As a pleiotropic cytokine with chemokine-like and enzymatic functions, MIF is widely expressed and released by immune and non-immune 
cells. There is ample evidence suggesting MIF acting as an essential mediator of inflammatory disease states, by binding to its functional membrane receptors. 25 More recently, MIF has emerged as a key player in the pathogenesis of cardiovascular diseases. We have previously shown that MIF level was elevated in the heart during hypoxia and pressure overload, and protected against these injuries by regulating AMP-activated protein kinase pathway. 26 In contrast to its cardioprotective effects, the function of MIF in vascular disease seems to be detrimental. 27 MIF was shown to participate in the progression of atherosclerosis and pulmonary arterial hypertension, suggesting an eminent role of MIF in vascular remodelling of pulmonary and systemic circulation.
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In spite of the literature that addressed the role of MIF in vascular angiogenesis and pathogenesis, most of them payed their attentions to its proinflammatory property, and little is known regarding the regulatory effects of this cytokine on VSMC differentiation and biological functions that are necessarily required for the development and progression of multiple vascular diseases. Therefore, we first evaluated the alternation of MIF level during VSMC transition, and found that MIF expression was markedly upregulated both in vivo and in vitro. Incubation of recombinant MIF dramatically suppressed the expression of differentiation markers of both aortic and pulmonary smooth muscle cells, indicating the importance of MIF in this process. Interestingly, we observed that MIF secretion was significantly increased in PDGF-BB-treated dedifferentiated VSMC, and anti-MIF treatment reversed VSMC transition triggered by PDGF-BB, which suggests a potential autocrine effect of MIF in the regulation of VSMC dedifferentiation. The biological function of MIF on cell plasticity was mediated by CD74, which is reported as the major receptor for MIF. In addition, we showed that MIF dosedependently triggered VSMC migration that was associated with increased expression of MMP-2, but had no effect on cell proliferation. 
Likewise, perivascular administration of MIF resulted in the transition of VSMCs to a dedifferentiation state in vivo, which led to impaired vessel contraction, thus reinforced the role of MIF in the modulation of VSMC phenotype. Conversely, a preceding study has shown that MIF induced differentiation of endothelial cells to blood vessels. 28 Moreover, Kanzler et al. 29 reported MIF prompting in vitro differentiation of endothelial progenitor cells (EPCs) towards a smooth muscle cell lineage. Our data seemed to be contradictory to these observations. However, it should be noted that this work focused on the effect of MIF on plasticity alteration of matured VSMCs. Similarly, prior studies have shown that EPCs could differentiate into smooth muscle cells in the presence of PDGF-BB supplement, while it is a well-known inducer of VSMC proliferation and dedifferentiation. 30 A plausible explanation for the inconsistency between these observations might lie in the versatility and diversity of the cytokine functions and the intrinsic divergence in the research subjects. Notably, we showed that inhibition of MIF activity by the small molecular inhibitor blocked the process of VSMC dedifferentiation, retained the damaged contractile function, and inhibited remodelling. Intriguingly, a previous study showed that immunoneutralizing against MIF resulted in impaired atherosclerosis in apolipoprotein E-deficient mice undergoing vascular injury, accompanied by a reduction in a number of inflammatory factors. 10 Therefore, our finding underscored the possibility that anti-MIF therapy through biochemical inhibition might be a promising strategy for clinical prevention and treatment of phenotype-related vascular abnormalities.
Another important finding in our study is the participation of p68 protein in MIF-elicited VSMC dedifferentiation. The RNA helicases p68 protein is a prototypic member of the DEAD box family, which is capable of manipulating RNA structures and dissociating RNA-protein complexes. 19 Indeed, we found that both MIF incubation and p68 siRNA treatment downregulated microRNA-21 expression in VSMCs, which is an important regulator of VSMC differentiation (Supplementary material on line, Figure S12A and B). Besides its ability to rearrange RNA metabolism, p68 has been shown as a co-activator of several important transcription factors, and being further implicated in a variety of cellular processes, such as cell cycle control and tumorigenesis. 31 More recent evidence supports p68 as a major regulator governing cellular and organ differentiation/maturation. It has been reported that p68 expression was 32 found that p68 could synergize with steroid receptor RNA to coactivate MyoD, which is of critical importance for skeletal myogenesis. Although being shown as an essential modulator of microRNA maturation in VSMCs, the physiological and/or pathological role of p68 in vascular system is currently ill-defined. 33 In the present study, we demonstrated for the first time that p68 protein was downregulated in MIF-challenged VSMCs and vascular tissues by regulating MAPK pathway. Previous report demonstrated that MAPK regulated p68 cellular localization by phosphorylation of p68 at Ser(197) in mouse embryonic fibroblast cells. 34 Our present study found that MIF inhibited p68 protein and mRNA expressions through activating p38 and JNK MAPKs, indicating that, besides of regulation of p68 phosphorylation, transcriptional or post-transcriptional mechanisms might be involved in the process. By our genetic loss-and gain-of-function experiments, p68 was found to prompt the differentiation of VSMCs that was positively correlated with smooth muscle contractile gene expressions. Moreover, overexpression of p68 blunted MIF-mediated VSMC dedifferentiation, suggesting that the effect of MIF on VSMC dedifferentiation was dependent on MAPKsinduced suppression of p68.
In delineating how MIF altered VSMC plasticity through p68, we focused our attention on SRF, which is a vital prompter of VSMC differentiation by binding to CArG elements and consequently stimulating smooth muscle marker transcription. It has been reported that angiotensin II and PDGF-BB, regulate VSMC plasticity through SRF, which let us to hypothesize that MIF may also modulate VSMC-specific gene expression through the similar mechanisms. In accordance, results of our study indicated that both MIF stimulation and p68 ablation significantly decreased SRF protein, however, they did not affect the translocation of myocardin-related transcription factor A, which is an important SRF coactivator (data not shown). Reciprocally, overexpression of p68 reversed the reduction of SRF expression by MIF stimuli, implying that MIF-induced VSMC dedifferentiation was, at least partially, through downregulation of SRF via repressing p68. Remarkably, this observation was corroborated by our coimmunoprecipitation experiment that demonstrated a novel interplay between p68 and SRF. Indeed, the EMSA analysis also demonstrated that p68 overexpression attenuated MIFelicited suppression of SRF recruitment to the CArG box-containing VSMC promoter regions. Therefore, p68 might be a molecular partner of SRF, and repression of p68 by MIF consequently affected the molecular function of SRF as well, which in turn, leads to VSMC dedifferentiation. However, future studies are needed to further elucidate their binding motifs.
Limitation
This study has several limitations. First, cultured VSMC could switch from the contractile to synthetic phenotype when they were passaged, which could cause potential bias to the in vitro study. However, in each experiment, we have tried our best to use VSMC from the same passage which might reduce this bias. Furthermore, we did not determine the effects of MIF on VSMC dedifferentiation in other vascular models such as mechanical stress. However, we have shown the contribution of MIF to phenotypic transition in serum-, PDGF-BB-, and hypoxia-induced dedifferentiated VSMC models, and both aortic and pulmonary arterial SMC were used in these experiments. Thus we believe that the biological activity of MIF in VSMC dedifferentiation has been confirmed.
Conclusions
In summary, the present work defines a previously unknown role of MIF in regulating VSMC homeostasis, through a de novo pathway that it suppresses SRF expression in a p68-dependent manner. Anti-MIF treatment reverses VSMC dedifferentiation, preserves vascular function, and inhibits arterial remodelling. Our results clearly uncover an important link between MIF and VSMC dedifferentiation, and offer it as being a viable therapeutic target in phenotype-related vascular abnormalities.
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